Alector, Inc.

As of November 8, 2022, Alector, Inc. is considered overvalued and risky due to its high Price to Book Value and EV to EBIT ratios, significant losses reflected in a negative ROE, and underperformance compared to peers and the S&P 500.

As of November 8, 2022, Alector, Inc. is considered overvalued and has a risky valuation grade due to its negative P/E ratio and poor financial metrics, with a year-to-date return of -27.25%, significantly underperforming the S&P 500.

As of May 16, 2025, Alector, Inc. shows a mildly bearish trend overall, with mixed signals from various indicators suggesting a cautious approach due to short-term bearishness outweighing longer-term bullish momentum.

As of March 2022, Alector, Inc.'s management team includes Dr. Tillman Gerngross (Chairman and Co-Founder), Dr. Arnon Rosenthal (CEO and Co-Founder), and several independent directors: Mr. Louis Lavigne, Dr. Paula Hammond, Mr. Terry McGuire, Dr. Richard Scheller, and Mr. David Wehner. They oversee the company's strategic direction and operations.

Alector, Inc. is a clinical-stage biopharmaceutical company specializing in immuno-neurology, with a market cap of approximately $151.99 million and reported net sales of $4 million and a net loss of $40 million for Q1 2025. The company does not pay dividends and has a negative return on equity of -128.14%.

As of Jun 18, Alector, Inc. has a market capitalization of 151.99 million and reported net sales of 88.33 million with a net profit of -123.44 million over the latest four quarters. Shareholder's funds are 126.80 million and total assets are 468.30 million as of Dec 24.